| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autism Spectrum Disorder | 86 | 2026 | 164 | 19.320 |
Why?
|
| Autistic Disorder | 71 | 2026 | 115 | 15.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 52 | 2026 | 205 | 11.700 |
Why?
|
| Pregnancy | 127 | 2026 | 1565 | 5.730 |
Why?
|
| Female | 237 | 2026 | 12715 | 4.660 |
Why?
|
| Child, Preschool | 101 | 2026 | 1455 | 4.600 |
Why?
|
| Humans | 275 | 2026 | 17622 | 4.470 |
Why?
|
| Maternal Exposure | 24 | 2026 | 84 | 4.370 |
Why?
|
| Child | 111 | 2026 | 2485 | 4.160 |
Why?
|
| Male | 180 | 2026 | 10014 | 4.040 |
Why?
|
| Neurodevelopmental Disorders | 7 | 2026 | 13 | 3.970 |
Why?
|
| Case-Control Studies | 71 | 2025 | 1107 | 3.530 |
Why?
|
| Child Development Disorders, Pervasive | 19 | 2017 | 31 | 3.340 |
Why?
|
| Infant, Newborn | 82 | 2026 | 842 | 3.160 |
Why?
|
| Intellectual Disability | 14 | 2020 | 28 | 3.130 |
Why?
|
| Adult | 116 | 2026 | 7621 | 3.020 |
Why?
|
| California | 78 | 2026 | 2433 | 2.990 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2026 | 157 | 2.920 |
Why?
|
| Developmental Disabilities | 18 | 2025 | 57 | 2.720 |
Why?
|
| Infant | 62 | 2026 | 1228 | 2.630 |
Why?
|
| Environmental Pollutants | 15 | 2026 | 67 | 2.450 |
Why?
|
| Pregnancy Complications | 16 | 2026 | 208 | 2.340 |
Why?
|
| Mothers | 12 | 2023 | 105 | 2.100 |
Why?
|
| Cohort Studies | 66 | 2026 | 2502 | 2.090 |
Why?
|
| Stroke | 19 | 2016 | 309 | 2.080 |
Why?
|
| DNA Methylation | 12 | 2025 | 45 | 1.830 |
Why?
|
| Risk Factors | 66 | 2025 | 3291 | 1.820 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 9 | 2026 | 70 | 1.780 |
Why?
|
| Adolescent | 45 | 2026 | 3625 | 1.780 |
Why?
|
| Child Health | 12 | 2026 | 43 | 1.740 |
Why?
|
| Mental Disorders | 6 | 2026 | 276 | 1.600 |
Why?
|
| Young Adult | 33 | 2026 | 2538 | 1.580 |
Why?
|
| Delivery of Health Care | 9 | 2024 | 383 | 1.550 |
Why?
|
| Air Pollution | 6 | 2026 | 47 | 1.420 |
Why?
|
| Mass Screening | 5 | 2026 | 693 | 1.380 |
Why?
|
| Cytokines | 7 | 2024 | 30 | 1.370 |
Why?
|
| Health Status | 5 | 2026 | 291 | 1.340 |
Why?
|
| Fetal Blood | 11 | 2025 | 13 | 1.280 |
Why?
|
| Organophosphates | 7 | 2026 | 19 | 1.260 |
Why?
|
| Flame Retardants | 6 | 2026 | 20 | 1.250 |
Why?
|
| United States | 39 | 2026 | 3922 | 1.200 |
Why?
|
| Transition to Adult Care | 2 | 2020 | 11 | 1.190 |
Why?
|
| Gestational Age | 14 | 2026 | 119 | 1.160 |
Why?
|
| Immunoglobulin G | 4 | 2026 | 35 | 1.130 |
Why?
|
| Thyrotropin | 3 | 2024 | 7 | 1.120 |
Why?
|
| Placenta | 7 | 2024 | 20 | 1.110 |
Why?
|
| Bipolar Disorder | 2 | 2020 | 60 | 1.090 |
Why?
|
| Heart Diseases | 8 | 2015 | 71 | 1.090 |
Why?
|
| Surveys and Questionnaires | 14 | 2026 | 1296 | 1.080 |
Why?
|
| Maternal Age | 15 | 2020 | 74 | 1.070 |
Why?
|
| Immunoglobulin M | 3 | 2026 | 9 | 1.060 |
Why?
|
| Influenza, Human | 4 | 2017 | 294 | 1.040 |
Why?
|
| American Heart Association | 8 | 2015 | 48 | 1.010 |
Why?
|
| Algorithms | 3 | 2026 | 227 | 1.010 |
Why?
|
| Prospective Studies | 18 | 2026 | 1251 | 0.980 |
Why?
|
| Air Pollutants | 7 | 2026 | 59 | 0.970 |
Why?
|
| Electronic Health Records | 5 | 2026 | 719 | 0.940 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2026 | 369 | 0.930 |
Why?
|
| Mental Health Services | 3 | 2017 | 155 | 0.920 |
Why?
|
| Infant, Premature | 9 | 2019 | 59 | 0.920 |
Why?
|
| Antibodies, Viral | 1 | 2026 | 73 | 0.920 |
Why?
|
| Biomarkers | 12 | 2026 | 302 | 0.920 |
Why?
|
| Glucose Intolerance | 1 | 2025 | 46 | 0.920 |
Why?
|
| Sexual and Gender Minorities | 1 | 2026 | 31 | 0.910 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2026 | 384 | 0.910 |
Why?
|
| Diabetes, Gestational | 3 | 2025 | 328 | 0.880 |
Why?
|
| Depression | 9 | 2026 | 507 | 0.880 |
Why?
|
| Child Development | 9 | 2026 | 57 | 0.870 |
Why?
|
| Infant, Premature, Diseases | 4 | 2013 | 16 | 0.850 |
Why?
|
| Prenatal Care | 3 | 2017 | 129 | 0.840 |
Why?
|
| Environmental Exposure | 12 | 2024 | 123 | 0.830 |
Why?
|
| Premature Birth | 6 | 2026 | 136 | 0.820 |
Why?
|
| Cerebral Palsy | 9 | 2016 | 14 | 0.810 |
Why?
|
| Particulate Matter | 5 | 2026 | 36 | 0.800 |
Why?
|
| Fever | 2 | 2019 | 52 | 0.780 |
Why?
|
| Longitudinal Studies | 11 | 2026 | 686 | 0.770 |
Why?
|
| Brain | 10 | 2020 | 50 | 0.760 |
Why?
|
| Jaundice, Neonatal | 4 | 2019 | 17 | 0.740 |
Why?
|
| Risk Assessment | 8 | 2017 | 1093 | 0.740 |
Why?
|
| Sexual Health | 1 | 2022 | 2 | 0.730 |
Why?
|
| Residence Characteristics | 5 | 2026 | 256 | 0.730 |
Why?
|
| Retrospective Studies | 24 | 2026 | 2502 | 0.730 |
Why?
|
| Parents | 7 | 2024 | 301 | 0.720 |
Why?
|
| Pregnancy Outcome | 5 | 2026 | 162 | 0.700 |
Why?
|
| Neural Tube Defects | 6 | 2003 | 8 | 0.700 |
Why?
|
| Prevalence | 19 | 2024 | 830 | 0.690 |
Why?
|
| Pregnancy Trimester, First | 4 | 2017 | 43 | 0.690 |
Why?
|
| Early Diagnosis | 3 | 2019 | 36 | 0.670 |
Why?
|
| Immunity | 1 | 2020 | 6 | 0.670 |
Why?
|
| Epigenesis, Genetic | 10 | 2025 | 26 | 0.660 |
Why?
|
| Hypersensitivity | 2 | 2015 | 22 | 0.660 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 20 | 0.660 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 35 | 0.660 |
Why?
|
| Genetic Research | 1 | 2020 | 7 | 0.650 |
Why?
|
| Infertility | 2 | 2026 | 4 | 0.640 |
Why?
|
| Stress, Psychological | 4 | 2026 | 141 | 0.640 |
Why?
|
| Logistic Models | 15 | 2019 | 866 | 0.630 |
Why?
|
| Diet | 5 | 2025 | 355 | 0.620 |
Why?
|
| Vaccines | 4 | 2016 | 225 | 0.620 |
Why?
|
| Patient Selection | 2 | 2020 | 181 | 0.610 |
Why?
|
| Prenatal Diagnosis | 3 | 2015 | 20 | 0.590 |
Why?
|
| Heart Defects, Congenital | 4 | 2014 | 18 | 0.590 |
Why?
|
| Patient Participation | 1 | 2020 | 124 | 0.590 |
Why?
|
| Primary Health Care | 3 | 2026 | 729 | 0.590 |
Why?
|
| Comorbidity | 10 | 2025 | 552 | 0.580 |
Why?
|
| Anxiety Disorders | 3 | 2023 | 100 | 0.580 |
Why?
|
| Asthma | 3 | 2015 | 401 | 0.580 |
Why?
|
| Genome-Wide Association Study | 9 | 2026 | 255 | 0.570 |
Why?
|
| Cross-Sectional Studies | 10 | 2026 | 1295 | 0.570 |
Why?
|
| Pandemics | 5 | 2023 | 295 | 0.560 |
Why?
|
| Odds Ratio | 16 | 2019 | 631 | 0.550 |
Why?
|
| Child Behavior | 4 | 2026 | 25 | 0.540 |
Why?
|
| Vitamin D | 3 | 2026 | 76 | 0.530 |
Why?
|
| Language Development | 3 | 2026 | 4 | 0.530 |
Why?
|
| Paternal Age | 4 | 2020 | 9 | 0.530 |
Why?
|
| Risk | 9 | 2017 | 492 | 0.510 |
Why?
|
| Siblings | 6 | 2026 | 13 | 0.510 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2021 | 45 | 0.510 |
Why?
|
| Holoprosencephaly | 4 | 2002 | 5 | 0.500 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.500 |
Why?
|
| Cleft Palate | 4 | 2003 | 7 | 0.500 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 56 | 0.490 |
Why?
|
| Birth Intervals | 2 | 2015 | 7 | 0.490 |
Why?
|
| Behavior Therapy | 1 | 2017 | 125 | 0.490 |
Why?
|
| Chemokines | 3 | 2024 | 6 | 0.480 |
Why?
|
| Mercury | 2 | 2014 | 4 | 0.480 |
Why?
|
| Health Care Surveys | 1 | 2017 | 210 | 0.480 |
Why?
|
| Vaccination | 3 | 2017 | 726 | 0.470 |
Why?
|
| Phthalic Acids | 3 | 2026 | 15 | 0.470 |
Why?
|
| Esters | 5 | 2025 | 10 | 0.460 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2018 | 540 | 0.460 |
Why?
|
| Insurance, Health | 1 | 2017 | 169 | 0.450 |
Why?
|
| Sex Factors | 9 | 2023 | 599 | 0.450 |
Why?
|
| Clinical Competence | 1 | 2015 | 108 | 0.440 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2016 | 96 | 0.430 |
Why?
|
| Physicians | 2 | 2015 | 120 | 0.430 |
Why?
|
| Anxiety | 4 | 2023 | 162 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2016 | 147 | 0.420 |
Why?
|
| Health Care Costs | 3 | 2010 | 211 | 0.420 |
Why?
|
| Middle Aged | 15 | 2026 | 7954 | 0.410 |
Why?
|
| Environment | 6 | 2019 | 50 | 0.400 |
Why?
|
| Research Report | 3 | 2015 | 23 | 0.400 |
Why?
|
| Alcohol Drinking | 3 | 2025 | 354 | 0.400 |
Why?
|
| Congenital Abnormalities | 5 | 2001 | 27 | 0.400 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 301 | 0.390 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2024 | 26 | 0.390 |
Why?
|
| Social Behavior | 2 | 2024 | 21 | 0.380 |
Why?
|
| Sensitivity and Specificity | 4 | 2026 | 302 | 0.370 |
Why?
|
| Fetal Development | 3 | 2026 | 15 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 380 | 0.370 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2010 | 5 | 0.360 |
Why?
|
| Thimerosal | 2 | 2010 | 5 | 0.360 |
Why?
|
| Serotonin | 2 | 2011 | 6 | 0.360 |
Why?
|
| Fluorocarbons | 2 | 2025 | 20 | 0.360 |
Why?
|
| Paresis | 2 | 2014 | 4 | 0.360 |
Why?
|
| Infant, Low Birth Weight | 4 | 2026 | 30 | 0.350 |
Why?
|
| Ethnic Groups | 8 | 2016 | 443 | 0.350 |
Why?
|
| Smoke | 2 | 2025 | 7 | 0.350 |
Why?
|
| Incidence | 12 | 2016 | 1278 | 0.350 |
Why?
|
| Fetal Proteins | 2 | 2008 | 4 | 0.350 |
Why?
|
| Cognition | 4 | 2025 | 91 | 0.350 |
Why?
|
| Databases, Factual | 4 | 2021 | 304 | 0.350 |
Why?
|
| Air Pollution, Indoor | 2 | 2026 | 8 | 0.340 |
Why?
|
| Continental Population Groups | 7 | 2016 | 283 | 0.340 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1157 | 0.340 |
Why?
|
| Health | 3 | 2015 | 32 | 0.340 |
Why?
|
| Chronic Disease | 3 | 2022 | 398 | 0.330 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2023 | 12 | 0.320 |
Why?
|
| Child Behavior Disorders | 2 | 2026 | 17 | 0.320 |
Why?
|
| Aging | 3 | 2015 | 159 | 0.310 |
Why?
|
| Analgesics, Opioid | 2 | 2026 | 258 | 0.310 |
Why?
|
| Occupational Exposure | 4 | 2016 | 66 | 0.310 |
Why?
|
| Obesity | 5 | 2024 | 821 | 0.310 |
Why?
|
| Cerebral Hemorrhage | 3 | 2014 | 12 | 0.310 |
Why?
|
| Ultrasonography | 1 | 2009 | 34 | 0.300 |
Why?
|
| Nitrogen Dioxide | 2 | 2026 | 17 | 0.300 |
Why?
|
| Ozone | 2 | 2026 | 14 | 0.300 |
Why?
|
| Interleukin-6 | 3 | 2016 | 24 | 0.300 |
Why?
|
| Apolipoproteins E | 3 | 2013 | 9 | 0.300 |
Why?
|
| Meconium | 2 | 2020 | 2 | 0.290 |
Why?
|
| Bilirubin | 4 | 2016 | 30 | 0.290 |
Why?
|
| Phenotype | 9 | 2021 | 154 | 0.290 |
Why?
|
| Benzhydryl Compounds | 2 | 2026 | 27 | 0.290 |
Why?
|
| Abnormalities, Multiple | 2 | 2006 | 8 | 0.280 |
Why?
|
| Cardiomyopathies | 2 | 2013 | 9 | 0.280 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2008 | 2 | 0.280 |
Why?
|
| Phenols | 2 | 2026 | 39 | 0.280 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2013 | 23 | 0.280 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 3 | 0.280 |
Why?
|
| Health Maintenance Organizations | 4 | 2009 | 403 | 0.280 |
Why?
|
| Seizures | 2 | 2016 | 28 | 0.280 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 2 | 2016 | 32 | 0.270 |
Why?
|
| Genotype | 9 | 2024 | 224 | 0.270 |
Why?
|
| Computational Biology | 3 | 2020 | 26 | 0.270 |
Why?
|
| Predictive Value of Tests | 3 | 2026 | 346 | 0.270 |
Why?
|
| Brain Ischemia | 2 | 2016 | 37 | 0.270 |
Why?
|
| Vulnerable Populations | 2 | 2024 | 35 | 0.260 |
Why?
|
| Socioeconomic Factors | 7 | 2026 | 603 | 0.260 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2024 | 10 | 0.260 |
Why?
|
| Body Mass Index | 5 | 2024 | 959 | 0.260 |
Why?
|
| Cleft Lip | 3 | 2003 | 5 | 0.260 |
Why?
|
| Dehydroepiandrosterone | 2 | 2017 | 7 | 0.250 |
Why?
|
| Testosterone | 2 | 2017 | 21 | 0.250 |
Why?
|
| Infection | 1 | 2007 | 17 | 0.250 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 702 | 0.250 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 363 | 0.250 |
Why?
|
| Problem Behavior | 1 | 2026 | 3 | 0.250 |
Why?
|
| Fertilization in Vitro | 1 | 2026 | 2 | 0.250 |
Why?
|
| Fungi | 1 | 2026 | 1 | 0.240 |
Why?
|
| Plasticizers | 1 | 2026 | 5 | 0.240 |
Why?
|
| Feeding Behavior | 3 | 2009 | 163 | 0.240 |
Why?
|
| Phototherapy | 2 | 2016 | 23 | 0.240 |
Why?
|
| Hyperbilirubinemia, Neonatal | 2 | 2016 | 17 | 0.240 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2026 | 7 | 0.240 |
Why?
|
| Registries | 4 | 2025 | 475 | 0.240 |
Why?
|
| Databases, Pharmaceutical | 1 | 2016 | 6 | 0.240 |
Why?
|
| Pediatric Obesity | 2 | 2025 | 101 | 0.240 |
Why?
|
| Vitamin D Deficiency | 1 | 2026 | 24 | 0.240 |
Why?
|
| Population Dynamics | 1 | 2026 | 7 | 0.240 |
Why?
|
| Immunization Schedule | 2 | 2016 | 127 | 0.240 |
Why?
|
| Sexism | 1 | 2025 | 2 | 0.240 |
Why?
|
| Wildfires | 1 | 2025 | 2 | 0.240 |
Why?
|
| CpG Islands | 4 | 2018 | 22 | 0.230 |
Why?
|
| Maternal Health | 1 | 2025 | 5 | 0.230 |
Why?
|
| Genetic Variation | 1 | 2026 | 82 | 0.230 |
Why?
|
| Aluminum | 1 | 2015 | 15 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 1 | 2026 | 55 | 0.230 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 19 | 0.230 |
Why?
|
| Dietary Exposure | 1 | 2025 | 1 | 0.230 |
Why?
|
| Health Services | 1 | 2006 | 110 | 0.230 |
Why?
|
| Metals, Heavy | 2 | 2024 | 3 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2025 | 21 | 0.230 |
Why?
|
| DNA-Binding Proteins | 1 | 2025 | 30 | 0.230 |
Why?
|
| Language | 1 | 2025 | 52 | 0.230 |
Why?
|
| Racism | 1 | 2025 | 22 | 0.230 |
Why?
|
| Wounds, Gunshot | 1 | 2025 | 18 | 0.230 |
Why?
|
| Firearms | 1 | 2025 | 32 | 0.220 |
Why?
|
| Age Factors | 6 | 2023 | 874 | 0.220 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2014 | 13 | 0.220 |
Why?
|
| Food Assistance | 1 | 2025 | 10 | 0.220 |
Why?
|
| Nicotine | 1 | 2025 | 27 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 109 | 0.220 |
Why?
|
| Hearing Loss | 1 | 2025 | 19 | 0.220 |
Why?
|
| Rural Population | 1 | 2025 | 58 | 0.210 |
Why?
|
| Oxytocin | 1 | 2024 | 4 | 0.210 |
Why?
|
| Substance-Related Disorders | 3 | 2016 | 417 | 0.210 |
Why?
|
| Depressive Disorder | 1 | 2016 | 186 | 0.210 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 10 | 0.210 |
Why?
|
| Birth Certificates | 5 | 2014 | 24 | 0.210 |
Why?
|
| Diseases in Twins | 2 | 2014 | 15 | 0.210 |
Why?
|
| Multivariate Analysis | 9 | 2011 | 527 | 0.200 |
Why?
|
| Cardiology | 1 | 2013 | 28 | 0.200 |
Why?
|
| Principal Component Analysis | 3 | 2018 | 24 | 0.200 |
Why?
|
| Infertility, Female | 2 | 2017 | 11 | 0.200 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2023 | 1 | 0.200 |
Why?
|
| Demography | 3 | 2020 | 92 | 0.200 |
Why?
|
| Birth Rate | 1 | 2013 | 3 | 0.200 |
Why?
|
| Public Health | 1 | 2024 | 84 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2021 | 107 | 0.200 |
Why?
|
| Child Health Services | 3 | 2009 | 107 | 0.190 |
Why?
|
| Anesthesia | 1 | 2022 | 2 | 0.190 |
Why?
|
| Biological Products | 1 | 2022 | 6 | 0.190 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 7 | 0.190 |
Why?
|
| Reproductive Health | 1 | 2022 | 10 | 0.180 |
Why?
|
| Apolipoproteins B | 1 | 2002 | 6 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2009 | 163 | 0.180 |
Why?
|
| Research Design | 3 | 2019 | 337 | 0.180 |
Why?
|
| Cholesterol | 1 | 2002 | 82 | 0.180 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2011 | 15 | 0.180 |
Why?
|
| Managed Care Programs | 2 | 2016 | 300 | 0.170 |
Why?
|
| Water Pollutants | 1 | 2001 | 1 | 0.170 |
Why?
|
| Nitrates | 1 | 2001 | 9 | 0.170 |
Why?
|
| Water Supply | 1 | 2001 | 8 | 0.170 |
Why?
|
| Fishes | 1 | 2021 | 10 | 0.170 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 8 | 0.170 |
Why?
|
| Caffeine | 1 | 2021 | 18 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 84 | 0.170 |
Why?
|
| Androgens | 1 | 2020 | 14 | 0.170 |
Why?
|
| Sexual Behavior | 1 | 2022 | 129 | 0.170 |
Why?
|
| Disabled Persons | 2 | 2024 | 35 | 0.170 |
Why?
|
| Neurogenesis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Genes, X-Linked | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cerebral Infarction | 2 | 2009 | 6 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 11 | 0.160 |
Why?
|
| Androstenedione | 2 | 2017 | 3 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2011 | 248 | 0.160 |
Why?
|
| Mental Health | 2 | 2022 | 163 | 0.160 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2026 | 55 | 0.160 |
Why?
|
| Pesticides | 2 | 2016 | 8 | 0.160 |
Why?
|
| Audiovisual Aids | 1 | 2009 | 2 | 0.160 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 10 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2009 | 22 | 0.160 |
Why?
|
| Marijuana Use | 3 | 2024 | 37 | 0.160 |
Why?
|
| Communication | 1 | 2021 | 181 | 0.160 |
Why?
|
| Patient Discharge | 2 | 2008 | 154 | 0.160 |
Why?
|
| Neonatal Screening | 1 | 2019 | 12 | 0.160 |
Why?
|
| Autoimmunity | 1 | 2019 | 4 | 0.160 |
Why?
|
| Smoking | 4 | 2015 | 420 | 0.150 |
Why?
|
| Chromatin | 1 | 2019 | 6 | 0.150 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 446 | 0.150 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2019 | 5 | 0.150 |
Why?
|
| Outcome Assessment (Health Care) | 4 | 2010 | 213 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 42 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 64 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 5 | 0.150 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 85 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 2 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 23 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 7 | 0.150 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2007 | 4 | 0.140 |
Why?
|
| Students, Medical | 1 | 2009 | 34 | 0.140 |
Why?
|
| Vitamins | 4 | 2022 | 59 | 0.140 |
Why?
|
| Data Collection | 4 | 2014 | 234 | 0.140 |
Why?
|
| Blood Buffy Coat | 1 | 2018 | 1 | 0.140 |
Why?
|
| Catchment Area (Health) | 2 | 2009 | 8 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 20 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 27 | 0.140 |
Why?
|
| Dysentery | 1 | 2008 | 1 | 0.140 |
Why?
|
| Alkanesulfonic Acids | 1 | 2018 | 3 | 0.140 |
Why?
|
| Caprylates | 1 | 2018 | 4 | 0.140 |
Why?
|
| Chorionic Villi | 1 | 2017 | 1 | 0.140 |
Why?
|
| Length of Stay | 1 | 2008 | 182 | 0.140 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2017 | 2 | 0.140 |
Why?
|
| Infertility, Male | 1 | 2017 | 3 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2008 | 72 | 0.140 |
Why?
|
| Maternal Inheritance | 1 | 2017 | 1 | 0.140 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2008 | 13 | 0.130 |
Why?
|
| Veins | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cross Infection | 1 | 2008 | 24 | 0.130 |
Why?
|
| Clostridium difficile | 1 | 2008 | 22 | 0.130 |
Why?
|
| Arteries | 1 | 2017 | 8 | 0.130 |
Why?
|
| Hispanic Americans | 1 | 2009 | 370 | 0.130 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2017 | 12 | 0.130 |
Why?
|
| Hazardous Waste | 1 | 1997 | 1 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2007 | 33 | 0.130 |
Why?
|
| Ethanol | 1 | 2017 | 21 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2007 | 23 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2009 | 260 | 0.130 |
Why?
|
| Fetus | 1 | 2017 | 5 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2009 | 92 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 67 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 45 | 0.130 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 3 | 0.130 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 4 | 0.130 |
Why?
|
| Pregnant Women | 1 | 2017 | 46 | 0.130 |
Why?
|
| Androsterone | 1 | 2016 | 1 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 2 | 0.130 |
Why?
|
| Asthma, Occupational | 1 | 2016 | 1 | 0.130 |
Why?
|
| Parity | 2 | 2014 | 57 | 0.130 |
Why?
|
| Air Pollutants, Occupational | 1 | 2016 | 15 | 0.130 |
Why?
|
| Health Promotion | 1 | 2009 | 293 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 28 | 0.120 |
Why?
|
| Interleukin-4 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2016 | 6 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2016 | 15 | 0.120 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 5 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 50 | 0.120 |
Why?
|
| Asperger Syndrome | 2 | 2007 | 4 | 0.120 |
Why?
|
| Psychometrics | 3 | 2021 | 119 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 152 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 44 | 0.120 |
Why?
|
| Gene-Environment Interaction | 2 | 2016 | 21 | 0.120 |
Why?
|
| Occupations | 2 | 2013 | 15 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 69 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 142 | 0.110 |
Why?
|
| Alcoholism | 1 | 2009 | 333 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.110 |
Why?
|
| Telomere | 1 | 2015 | 18 | 0.110 |
Why?
|
| Intelligence | 4 | 2020 | 9 | 0.110 |
Why?
|
| Spermatozoa | 1 | 2015 | 4 | 0.110 |
Why?
|
| Dried Blood Spot Testing | 1 | 2015 | 1 | 0.110 |
Why?
|
| Caregivers | 3 | 2023 | 136 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 3 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 689 | 0.110 |
Why?
|
| Genomics | 1 | 2015 | 56 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2007 | 208 | 0.110 |
Why?
|
| Epilepsy | 1 | 2014 | 15 | 0.110 |
Why?
|
| Family Health | 1 | 2015 | 45 | 0.110 |
Why?
|
| Maternal Behavior | 1 | 2014 | 12 | 0.110 |
Why?
|
| Reproductive Behavior | 1 | 2014 | 1 | 0.110 |
Why?
|
| Internship and Residency | 2 | 1993 | 58 | 0.100 |
Why?
|
| Aged | 5 | 2015 | 6223 | 0.100 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2006 | 9 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2011 | 34 | 0.100 |
Why?
|
| Electromagnetic Fields | 1 | 1993 | 4 | 0.100 |
Why?
|
| Models, Chemical | 1 | 2013 | 1 | 0.100 |
Why?
|
| Volatile Organic Compounds | 1 | 2013 | 2 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 321 | 0.100 |
Why?
|
| Dust | 1 | 2013 | 21 | 0.100 |
Why?
|
| Linear Models | 3 | 2020 | 204 | 0.100 |
Why?
|
| Cephalometry | 1 | 2013 | 1 | 0.100 |
Why?
|
| Megalencephaly | 1 | 2013 | 2 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 1993 | 7 | 0.100 |
Why?
|
| Head | 1 | 2013 | 6 | 0.100 |
Why?
|
| Twins | 1 | 2013 | 11 | 0.100 |
Why?
|
| Work Schedule Tolerance | 1 | 1993 | 8 | 0.100 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 144 | 0.100 |
Why?
|
| Sex Characteristics | 3 | 2021 | 66 | 0.100 |
Why?
|
| Internal Medicine | 1 | 1993 | 22 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2025 | 14 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 1993 | 204 | 0.100 |
Why?
|
| Epigenomics | 3 | 2017 | 6 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 24 | 0.100 |
Why?
|
| Cannabis | 2 | 2025 | 83 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 91 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2020 | 228 | 0.090 |
Why?
|
| Educational Status | 3 | 2016 | 177 | 0.090 |
Why?
|
| Gene Frequency | 3 | 2013 | 39 | 0.090 |
Why?
|
| Halogenated Diphenyl Ethers | 2 | 2023 | 10 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2025 | 214 | 0.090 |
Why?
|
| Quantitative Trait Loci | 2 | 2025 | 38 | 0.090 |
Why?
|
| Social Class | 3 | 2024 | 117 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2011 | 2 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 73 | 0.090 |
Why?
|
| Recurrence | 3 | 2014 | 166 | 0.090 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 8 | 0.090 |
Why?
|
| Twins, Monozygotic | 1 | 2011 | 11 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 24 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2006 | 107 | 0.090 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 82 | 0.090 |
Why?
|
| Molecular Epidemiology | 3 | 2015 | 44 | 0.080 |
Why?
|
| Family | 2 | 2023 | 111 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 215 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2020 | 46 | 0.080 |
Why?
|
| Sudden Infant Death | 1 | 1990 | 10 | 0.080 |
Why?
|
| Time Factors | 3 | 2014 | 1038 | 0.080 |
Why?
|
| Syndrome | 2 | 2002 | 28 | 0.080 |
Why?
|
| Zinc | 1 | 1999 | 2 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2007 | 22 | 0.080 |
Why?
|
| Forms and Records Control | 1 | 2009 | 7 | 0.080 |
Why?
|
| Government Agencies | 1 | 2009 | 5 | 0.080 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 65 | 0.070 |
Why?
|
| Hobbies | 1 | 1999 | 1 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 1999 | 85 | 0.070 |
Why?
|
| Maternal Welfare | 1 | 2009 | 12 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Quality of Life | 2 | 2023 | 505 | 0.070 |
Why?
|
| Birth Order | 2 | 2014 | 4 | 0.070 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Disabled Children | 1 | 2009 | 28 | 0.070 |
Why?
|
| Forecasting | 2 | 2002 | 68 | 0.070 |
Why?
|
| Umbilical Cord | 2 | 2018 | 4 | 0.070 |
Why?
|
| Fetal Growth Retardation | 2 | 2006 | 11 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2009 | 38 | 0.070 |
Why?
|
| Regression (Psychology) | 1 | 2008 | 1 | 0.070 |
Why?
|
| Sleep Wake Disorders | 1 | 2008 | 33 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 3 | 0.070 |
Why?
|
| Women's Health | 1 | 2009 | 198 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 1976 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2008 | 35 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2007 | 72 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2009 | 23 | 0.060 |
Why?
|
| Animals | 2 | 2021 | 285 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 6 | 0.060 |
Why?
|
| Leptin | 1 | 2007 | 26 | 0.060 |
Why?
|
| Clomiphene | 1 | 2006 | 1 | 0.060 |
Why?
|
| Spina Bifida Occulta | 1 | 2006 | 1 | 0.060 |
Why?
|
| Spina Bifida Cystica | 1 | 2006 | 1 | 0.060 |
Why?
|
| Fertility Agents, Female | 1 | 2006 | 2 | 0.060 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Neurotoxins | 1 | 2006 | 1 | 0.060 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 2 | 0.060 |
Why?
|
| Term Birth | 1 | 2006 | 9 | 0.060 |
Why?
|
| Endocrine Disruptors | 1 | 2006 | 9 | 0.060 |
Why?
|
| Fungicides, Industrial | 1 | 2026 | 1 | 0.060 |
Why?
|
| Herbicides | 1 | 2026 | 1 | 0.060 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2026 | 4 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 7 | 0.060 |
Why?
|
| Insecticides | 1 | 2026 | 8 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 79 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2014 | 98 | 0.060 |
Why?
|
| Overweight | 2 | 2023 | 266 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 120 | 0.060 |
Why?
|
| Denmark | 1 | 2025 | 19 | 0.060 |
Why?
|
| Safety | 1 | 2016 | 43 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 28 | 0.060 |
Why?
|
| Immunization | 1 | 2016 | 71 | 0.060 |
Why?
|
| Folic Acid | 2 | 2022 | 29 | 0.060 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 68 | 0.060 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2024 | 4 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2013 | 174 | 0.050 |
Why?
|
| Motor Skills Disorders | 1 | 2004 | 1 | 0.050 |
Why?
|
| Age Distribution | 2 | 2013 | 230 | 0.050 |
Why?
|
| Mercury Poisoning | 1 | 2004 | 1 | 0.050 |
Why?
|
| Risk Adjustment | 2 | 2009 | 19 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 23 | 0.050 |
Why?
|
| Hair | 1 | 2004 | 7 | 0.050 |
Why?
|
| Mother-Child Relations | 2 | 2015 | 13 | 0.050 |
Why?
|
| Social Participation | 1 | 2024 | 3 | 0.050 |
Why?
|
| Income | 2 | 2016 | 86 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2024 | 7 | 0.050 |
Why?
|
| Morbidity | 1 | 2004 | 59 | 0.050 |
Why?
|
| Sports | 1 | 2024 | 22 | 0.050 |
Why?
|
| Phosphates | 1 | 2024 | 5 | 0.050 |
Why?
|
| Bias | 1 | 2004 | 95 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 87 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 41 | 0.050 |
Why?
|
| Feeding and Eating Disorders | 1 | 2003 | 16 | 0.050 |
Why?
|
| Chorioamnionitis | 1 | 2003 | 18 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 8 | 0.050 |
Why?
|
| Environmental Health | 1 | 2023 | 8 | 0.050 |
Why?
|
| Unemployment | 1 | 2003 | 12 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 1 | 0.050 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2023 | 1 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2023 | 1 | 0.050 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2023 | 4 | 0.050 |
Why?
|
| Sociological Factors | 1 | 2023 | 2 | 0.050 |
Why?
|
| Antipyretics | 1 | 2013 | 4 | 0.050 |
Why?
|
| Twin Studies as Topic | 1 | 2002 | 3 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2013 | 23 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 17 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 104 | 0.050 |
Why?
|
| San Francisco | 2 | 2013 | 62 | 0.050 |
Why?
|
| Age of Onset | 3 | 2007 | 74 | 0.050 |
Why?
|
| Infant Food | 1 | 2011 | 7 | 0.050 |
Why?
|
| Poverty | 1 | 2003 | 171 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2014 | 228 | 0.040 |
Why?
|
| Drug Utilization | 2 | 2019 | 119 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2011 | 19 | 0.040 |
Why?
|
| Lactation | 1 | 2011 | 38 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2016 | 137 | 0.040 |
Why?
|
| Weight Gain | 1 | 2023 | 165 | 0.040 |
Why?
|
| Multiple Birth Offspring | 1 | 2001 | 1 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2001 | 1 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2001 | 2 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 34 | 0.040 |
Why?
|
| Anencephaly | 1 | 2001 | 1 | 0.040 |
Why?
|
| Spinal Dysraphism | 1 | 2001 | 1 | 0.040 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2011 | 40 | 0.040 |
Why?
|
| Mortality | 1 | 2011 | 116 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 2 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 4 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 1991 | 70 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 46 | 0.040 |
Why?
|
| Acyclovir | 1 | 1990 | 5 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2020 | 69 | 0.040 |
Why?
|
| Duffy Blood-Group System | 1 | 2020 | 1 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2020 | 1 | 0.040 |
Why?
|
| Chemokine CXCL6 | 1 | 2020 | 1 | 0.040 |
Why?
|
| European Continental Ancestry Group | 2 | 2013 | 470 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 6 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 4 | 0.040 |
Why?
|
| Multilingualism | 1 | 2009 | 8 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2010 | 17 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 163 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 60 | 0.040 |
Why?
|
| Body Weight | 1 | 2001 | 203 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 9 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 49 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2013 | 7 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2009 | 85 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2010 | 66 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 46 | 0.040 |
Why?
|
| Gambling | 1 | 2009 | 1 | 0.040 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 1 | 0.040 |
Why?
|
| Colorado | 1 | 2009 | 170 | 0.040 |
Why?
|
| Street Drugs | 1 | 2009 | 12 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 262 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 135 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 2008 | 4 | 0.040 |
Why?
|
| Cost Savings | 1 | 2008 | 20 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 609 | 0.040 |
Why?
|
| Photography | 1 | 2018 | 11 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 16 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2009 | 101 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2009 | 147 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2017 | 4 | 0.030 |
Why?
|
| Central Nervous System Depressants | 1 | 2017 | 2 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 104 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 39 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 22 | 0.030 |
Why?
|
| Cyanides | 1 | 1997 | 1 | 0.030 |
Why?
|
| Military Personnel | 1 | 1997 | 12 | 0.030 |
Why?
|
| Lung | 1 | 2017 | 57 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2007 | 84 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 2 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 6 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 6 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 17 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 54 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 45 | 0.030 |
Why?
|
| Trisomy | 1 | 1996 | 3 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1996 | 3 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 7 | 0.030 |
Why?
|
| Face | 1 | 1996 | 5 | 0.030 |
Why?
|
| Research | 1 | 2006 | 60 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 197 | 0.030 |
Why?
|
| New York City | 2 | 1993 | 24 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2006 | 3 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 73 | 0.030 |
Why?
|
| Survival Rate | 1 | 2006 | 252 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2006 | 40 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 114 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 2 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2006 | 57 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 70 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 61 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 8 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 40 | 0.030 |
Why?
|
| Fathers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Preconception Care | 2 | 2000 | 44 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 65 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 159 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 3 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 33 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 31 | 0.030 |
Why?
|
| Exercise | 1 | 2009 | 538 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 33 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 102 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 15 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 34 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 17 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2013 | 25 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 1993 | 8 | 0.030 |
Why?
|
| Uganda | 1 | 2013 | 8 | 0.020 |
Why?
|
| Developing Countries | 1 | 2013 | 12 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 171 | 0.020 |
Why?
|
| Paternal Exposure | 1 | 2013 | 4 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 2013 | 2 | 0.020 |
Why?
|
| Prothrombin | 1 | 2013 | 2 | 0.020 |
Why?
|
| Factor V | 1 | 2013 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 27 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 268 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 2 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 33 | 0.020 |
Why?
|
| Epidemiology | 1 | 1991 | 6 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2010 | 3 | 0.020 |
Why?
|
| Teaching | 1 | 1991 | 15 | 0.020 |
Why?
|
| Education, Medical | 1 | 1991 | 25 | 0.020 |
Why?
|
| Ethylmercury Compounds | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 25 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 6 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 545 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 64 | 0.020 |
Why?
|
| Hospital Records | 1 | 1990 | 4 | 0.020 |
Why?
|
| Hospitalization | 1 | 2006 | 831 | 0.020 |
Why?
|
| Korea | 1 | 1990 | 9 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 103 | 0.020 |
Why?
|
| Japan | 1 | 1990 | 14 | 0.020 |
Why?
|
| Philippines | 1 | 1990 | 25 | 0.020 |
Why?
|
| Culture | 1 | 1990 | 30 | 0.020 |
Why?
|
| Vietnam | 1 | 1990 | 42 | 0.020 |
Why?
|
| China | 1 | 1990 | 132 | 0.020 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1999 | 8 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 1999 | 45 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 149 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 207 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2009 | 11 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 86 | 0.020 |
Why?
|
| Language Disorders | 1 | 2008 | 3 | 0.020 |
Why?
|
| Social Behavior Disorders | 1 | 2008 | 3 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2007 | 1 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 3 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2007 | 11 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 45 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 37 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 242 | 0.020 |
Why?
|
| Teratogens | 1 | 2007 | 3 | 0.020 |
Why?
|
| Solvents | 1 | 2006 | 1 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 6 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2006 | 18 | 0.020 |
Why?
|
| Urban Health | 1 | 2006 | 36 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 37 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2006 | 32 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 486 | 0.010 |
Why?
|
| Heart Failure | 1 | 2011 | 414 | 0.010 |
Why?
|
| Haemophilus Vaccines | 1 | 2005 | 19 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 43 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 2005 | 8 | 0.010 |
Why?
|
| Hazardous Substances | 1 | 2004 | 3 | 0.010 |
Why?
|
| Asphyxia Neonatorum | 1 | 2003 | 2 | 0.010 |
Why?
|
| Australia | 1 | 2002 | 26 | 0.010 |
Why?
|
| Dyslexia | 1 | 1982 | 1 | 0.010 |
Why?
|
| Reading | 1 | 1982 | 6 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2001 | 14 | 0.010 |
Why?
|
| Herpes Genitalis | 1 | 1990 | 3 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 8 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 8 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 18 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 9 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2000 | 16 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2000 | 16 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1990 | 143 | 0.010 |
Why?
|
| Collective Bargaining | 1 | 1979 | 1 | 0.010 |
Why?
|
| Clinical Medicine | 1 | 1991 | 4 | 0.010 |
Why?
|
| Biometry | 1 | 1991 | 13 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1991 | 67 | 0.010 |
Why?
|
| Curriculum | 1 | 1991 | 54 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1990 | 324 | 0.000 |
Why?
|
| Psychosocial Deprivation | 1 | 1982 | 4 | 0.000 |
Why?
|
| Urban Population | 1 | 1982 | 111 | 0.000 |
Why?
|